ExpertiseUpdated on 19 November 2025
Tailored Biomarker Solutions for your Clinical Programs
CEO at CheckImmune GmbH
Berlin, Germany
About
Selection/validation of drug lead candidates
Application of a broad panel of customized and off-the-shelf biomarker tests using cutting-edge technologies for lead candidate selection.
Phase 0 studies
Proof-of-concept studies on biosamples from target patient populations (phase 0) to confirm selected biomarker test portfolios for following therapy monitoring.
Therapy monitoring
Therapy monitoring in clinical trials to check safety, PD/PK, patient stratfication with a wide range of validated assays as well as newly developed customized methods.
Data analysis and scientific & medical interpretation
CheckImmune is backed by a world-renowned team of experts with years of academic and commercial experience in the field of biomarkers.
Field
- DISEASE AREA | Cancer
- DISEASE AREA | Inflammation / Autoimmune Diseases
- DISEASE AREA | Infectious Diseases
- DISEASE AREA | Metabolic Diseases
- MEDICINE | Biomarker Discovery
- MEDICINE | Early Detection
- MEDICINE | Diagnostics
- MEDICINE | Cell Therapy
- MEDICINE | RNA-based Therapy
- MEDICINE | Therapy Monitoring
- TECHNOLOGY | (Single-cell) multi-omics
Organisation
Similar opportunities
Expertise
New Approach Methodologies (NAM) Training Program
- TECHNOLOGY | Other
- DISEASE AREA | Cancer
- DISEASE AREA | Other
- MEDICINE | Gene Therapy
- MEDICINE | Cell Therapy
- MEDICINE | Drug Screening
- TECHNOLOGY | Bioengineering
- MEDICINE | RNA-based Therapy
- MEDICINE | Drug Target Discovery
- DISEASE AREA | Metabolic Diseases
- DISEASE AREA | Infectious Diseases
- TECHNOLOGY | Personalized disease models
- DISEASE AREA | Inflammation / Autoimmune Diseases
Marty Steiger
Application Scientist at Dynamic42 GmbH
Germany
Expertise
- MEDICINE | Other
- TECHNOLOGY | Other
- DISEASE AREA | Cancer
- DISEASE AREA | Other
- MEDICINE | Diagnostics
- MEDICINE | Gene Therapy
- MEDICINE | Liquid Biopsy
- MEDICINE | Drug Screening
- MEDICINE | Early Detection
- MEDICINE | RNA-based Therapy
- MEDICINE | Biomarker Discovery
- MEDICINE | Drug Target Discovery
- DISEASE AREA | Infectious Diseases
- DISEASE AREA | Cardiovascular Diseases
Ismahen Ammar
Technical Sales Specialist at Illumina GmbH
Berlin, Germany
Investment
Selective Inhibitors of Genotoxic Stress Induced NFκB Pathway for Cancer Therapy
- Disease Area
- Seed & Development
- Biomedical Research, Medicine, Human Health
Beatrice Pöschel
Technologie-Managerin at Max Delbrück Center for Molecular Medicine
Berlin, Germany